Gain of Function p53 mutant R273H confers distinct methylation profiles and consequent partial or full EMT states to colon tumour
Harsha Rani, Seemadri SubhadarshiniiD, Mohit Kumar JollyiD, Vijayalakshmi Mahadevan
Abstract
p53 is the second most frequently mutated gene in colorectal cancer. While different p53 mutations have been correlated with metastasis, the distinct phenotypes exhibited by site-specific mutations of p53 are not well elucidated. Here, we analyse transcriptomic and methylation data from TCGA-COAD cohort to understand the epigenetic impact of three most prevalent hotspot mutations of p53 (R175H, R273H and R282W). We observed that p53 R273H mutation associates with a partial epithelial-mesenchymal transition (pEMT) state and metastatic progression. In vitro ChIP-seq experiments conducted on p53R27H harbouring HT29 cells revealed an enrichment of mutant p53 R273H at pEMT or mesenchymal gene sets. Further, simulations from a gene regulatory network incorporating the interactions of p53R273H with EMT regulators explain how this mutation shapes the phenotypic landscape accessible to cancer cells. Finally, single-cell transcriptomic analysis of colorectal tumours reveals R273H-linked enrichment of partial and mesenchymal EMT phenotypes across tumour subpopulations in CRC. Overall, we identified distinct epigenetic regulation regulating partial EMT and consequent aggressive behaviour triggered by p53R273H. These findings can help devise effective therapeutic strategies for p53 mutant specific colon tumours. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=177 SRC="FIGDIR/small/662954v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@7d424dorg.highwire.dtl.DTLVardef@18bfcaborg.highwire.dtl.DTLVardef@17950c8org.highwire.dtl.DTLVardef@1a698f9_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical Abstract CaptionC_FLOATNO Mutation in Tp53 at R273H associates with DNA hypermethylation and elevated pEMT and metastatic signatures as compared to R175 and R282W mutations in colon tumours suggesting of devising novel therapeutic intervention strategies based on p53 mutation profiles. C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of tumour suppressor p53 rewires enhancer landscape and governs oncogenic progression
Harsha Rani, Dimple Notani, Vijayalakshmi Mahadevan·bioRxiv·Jul 28, 2025
- Epigenetic reprogramming by promoter hypomethylation is linked to aberrant gene expression and transcriptomic plasticity in colorectal cancer
Luís Nunes, Ina A. Eilertsen, … Anita Sveen·bioRxiv·Nov 5, 2026
- TP53 status aligns with morphology and metaplastic programs in colorectal cancer organoids, and MDM2 P2 promoter usage reflects p53 activity
Takahiro Tsukui, Kento Shin, … Koji Tsuda·bioRxiv·Sep 29, 2026
- Colorectal cancer progression to metastasis is associated with dynamic genome-wide biphasic 5-hydroxymethylcytosine accumulation.
Ben Murcott, Floris Honig, … Adele Murrell·BMC BiologyPeer-reviewed·Apr 16, 2025
- Aggressive KRAS mutations direct TGF-β response towards partial EMT in patient-derived colorectal cancer tumoroids
Theresia Mair, Philip König, … Gerda Egger·Molecular OncologyPeer-reviewed·Mar 11, 2025
- Canonical TGFβ signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT